Clinical Trials

599 enrolled

Prostatic Neoplasms

NCT06136624 2026-03-11

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT06136650 2026-03-09

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

675 enrolled

Neoplasms, Prostatic Neoplasms

NCT06551324 2026-03-04

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT06629779 2026-03-04

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

900 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT07028853 2026-03-04

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT04076059 2026-02-06

China ARCHES

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT04455750 2026-02-05

CASPAR

61 enrolled

Prostatic Neoplasms

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT06764485 2026-01-28

rechARge

960 enrolled

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT06120491 2026-01-21

EvoPAR-PR01

1,800 enrolled

Prostatic Neoplasms

NCT06592924 2026-01-14

TRIPLE-SWITCH

830 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT05112965 2026-01-07

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

49 enrolled

Tumor-Agnostic

Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 1 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT04934722 2025-10-01

KEYNOTE-991

186 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02194842 2025-09-19

PEACE III

446 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

439 enrolled

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT02446444 2025-05-30

ENZARAD

802 enrolled

Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03903835 2025-04-09

ProBio

750 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02288247 2025-04-08

PRESIDE

688 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02446405 2025-02-06

ENZAMET

1,125 enrolled

Prostatic Neoplasms

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

500 enrolled

Genital Diseases, Male, Prostatic Diseases

NCT03850795 2024-08-19

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

104 enrolled

Prostate Cancer Metastatic

NCT03016312 2024-08-09

IMbassador250

759 enrolled 22 charts

Prostatic Neoplasms, Castration-Resistant

NCT04844749 2024-02-05

VERACITY

105 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

74 enrolled

Prostatic Neoplasms, Patient Preference

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

387 enrolled 16 charts 2 FDA

Metastatic Castration-resistant Prostate Cancer

NCT01949337 2023-09-28

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Phase 3 Unknown

1,311 enrolled 12 charts

Prostatic Neoplasms

NCT04139772 2023-03-24

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Phase 3 Unknown

18 enrolled

Metastatic Castration-resistent Prostate Cancer

NCT02438007 2023-03-15

ARMOR3-SV

953 enrolled

Prostatic Neoplasms

NCT01212991 2020-03-17

PREVAIL

1,717 enrolled 20 charts